First in Man Study With SLV342

Abbott

Status and phase: Terminated; Phase 1

Conditions: Pharmacokinetics

Treatments: Drug: placebo; Drug: SLV342

Study type: Interventional

Funder types: Industry

Identifiers

NCT00985478

2009-014245-88 (EudraCT Number)

S342.1.001

Details and patient eligibility

About

First in man study with single and multiple rising doses with SLV342

Enrollment: 48 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Healthy

Exclusion Criteria

• Not healthy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

48 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

SLV342 suspension or capsule

Treatment:

Drug: SLV342

B

Placebo Comparator group

Description:

matching placebo

Treatment:

Drug: placebo